Schweizer Firma erhält Felix Burda Award für Bluttest, der Darmkrebs erkennt Ein Biotech-Unternehmen hat einen Bluttest entwickelt, der Darmkrebs und dessen Vorstufen mit hoher Wahrscheinlichkeit erkennt. Die Basis dafür bilden Biomarker im Blut. Für diesen Fortschritt in der Darmkrebs-Vorsorge erhalten sie den Felix Burda Award 2021. Im zweiten Teil der virtuellen Preisverleihung geht der
Novigenix Wins the 2021 Felix Burda Award in Medicine & Science • Category ‘Innovation in Immuno-Transcriptomics for Early Detection of Colorectal Cancer’ • Award recognizes excellence in innovation and impact in early detection of cancer LAUSANNE, SWITZERLAND - July 22, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision
Total amount up to €1 million awarded to consortium of leading cancer centers and innovative healthcare companies LAUSANNE, SWITZERLAND – 07:00 CET, December 22, 2020 Novigenix SA Switzerland, a pioneer in Immuno-Transcriptomics for precision medicine today announced that a consortium, including PamGene International BV and Radboud University (The Netherlands), has been awarded a grant up to €1 million
Newly discovered blood signature presented at ESMO 2020 LAUSANNE, SWITZERLAND – 07:00 CET, September 17th, 2020 – Novigenix SA, a pioneer in Immuno-Transcriptomics for precision oncology, today announced a new Immuno-Transcriptomic signature for predicting response to immunotherapy in metastatic urothelial cancer patients. The data are presented at the European Society for Medical Oncology (ESMO)
Total amount up to €1 million awarded to consortium of leading cancer centers and innovative healthcare companies LAUSANNE, SWITZERLAND - 07:00 CET, January 21, 2020 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced that a consortium, including Maastricht University (The Netherlands),
Immune cell type specific profiles correlate with traditional blood cell count method LAUSANNE, SWITZERLAND - 07:00 CET, December 11, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced the development of a new immune cell type specific Immuno-Transcriptomic signature for the detection
Test to measure response to radiopharmaceutical therapy LAUSANNE, SWITZERLAND - 07:00 CET, October 14, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology.
First liquid biopsy test reimbursed in Switzerland for colon cancer screening through private outpatient supplementary insurance product offered by Helsana LAUSANNE, SWITZERLAND - 07:00 CET, October 9, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine. today announced that Helsana, the leading health insurance
Data on test’s newly discovered blood signature presented at ESMO 2019 LAUSANNE, SWITZERLAND - 07:00 CET, September 30, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced promising data from a study of a new Immuno-Transcriptomic signature for early detection of colorectal
Company Launches New Website to Enhance New Strategy Company to present at the Convergence of Oncology meeting in Lausanne LAUSANNE, SWITZERLAND - 07:00 CET, September 10, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced the discovery of a new molecular signature